Breakthrough injection may regrow cartilage and halt arthritis progression
A new injection treatment could help regrow cartilage and prevent arthritis. Early tests show it may also lower the risk of osteoarthritis after injuries like ACL tears. Researchers are now planning further trials to confirm its effectiveness in humans.
The treatment works by blocking a protein called 15-PGDH, which becomes more active with age. This protein weakens muscle stem cells and prevents cartilage repair. By injecting a 15-PGDH inhibitor into mouse joints, scientists observed thicker knee cartilage forming.
The same inhibitor has already passed Phase 1 clinical trials in oral form, where it successfully treated muscle weakness. The injection version 'reprograms' cells to produce functional cartilage, offering a potential solution for joint damage. If future trials succeed, regulatory approval could take between six and 18 months, based on standard timelines for similar therapies.
The treatment's ability to regenerate cartilage and reduce osteoarthritis risk marks a significant step forward. Further clinical trials will determine its safety and effectiveness in people. If approved, it could provide a new way to manage joint injuries and age-related cartilage loss.
